Evidence map›Paper›PMID 38650367›Full record

ArticleThe journal of pathology. Clinical research2024

Histopathological tumour microenvironment score independently predicts outcome in primary operable colorectal cancer.

Phimmada Hatthakarnkul, Kathryn Pennel, Peter Alexander, Hester van Wyk, Antonia Roseweir, Jitwadee Inthagard, Jennifer Hay, Ditte Andersen, Noori Maka, James Park and 4 more

Abstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Phimmada Hatthakarnkul *School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Kathryn Pennel *School of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0003-0186-1331
Peter AlexanderSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.
Hester van WykAcademic Unit of Surgery, University of Glasgow, UK.
Antonia RoseweirSchool of Medicine, University of Glasgow, Glasgow, UK.ORCID 0000-0001-6158-1564
Jitwadee InthagardSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.
Jennifer HayGlasgow Tissue Research Facility, Queen Elizabeth University Hospital, Glasgow, UK.
Ditte AndersenBioclavis Ltd, Queen Elizabeth University Hospital, Glasgow, UK.
Noori MakaDepartment of Pathology, Queen Elizabeth Hospital, Glasgow, UK.
James ParkDepartment of Surgery, Queen Elizabeth University Hospital, Glasgow, UK.
Campbell RoxburghSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.
Chanitra ThuwajitBiomedical Science Program, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Donald McMillanSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.
Joanne EdwardsSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-7192-6906

Funding

Cancer Research UK CTRQQR-2021/10000Cancer Research UK RRNPSF-JUL21/1D100010Chief Scientist Office EPD/22/13Medical Research Council MR/R502327
6 · The paper itself

Abstract

Colorectal cancer (CRC) is a heterogenous malignancy and research is focused on identifying novel ways to subtype patients. In this study, a novel classification system, tumour microenvironment score (TMS), was devised based on Klintrup-Mäkinen grade (KMG), tumour stroma percentage (TSP), and tumour budding. TMS was performed using a haematoxylin and eosin (H&E)-stained section from retrospective CRC discovery and validation cohorts (n = 1,030, n = 787). TMS0 patients had high KMG, TMS1 were low for KMG, TSP, and budding, TMS2 were high for budding, or TSP and TMS3 were high for TSP and budding. Scores were assessed for association with survival and clinicopathological characteristics. Mutational landscaping and Templated Oligo-Sequencing (TempO-Seq) profiling were performed to establish differences in the underlying biology of TMS. TMS was independently prognostic in both cohorts (p < 0.001, p < 0.001), with TMS3 predictive of the shortest survival times. TMS3 was associated with adverse clinical features including sidedness, local and distant recurrence, higher T stage, higher N stage, and presence of margin involvement. Gene set enrichment analysis of TempO-Seq data showed higher expression of genes associated with hallmarks of cancer pathways including epithelial to mesenchymal transition (p < 0.001), IL2 STAT5 signalling (p = 0.007), and angiogenesis (p = 0.017) in TMS3. Additionally, enrichment of immunosuppressive immune signatures was associated with TMS3 classification. In conclusion, TMS represents a novel and clinically relevant method for subtyping CRC patients from a single H&E-stained tumour section.

Indexed as

Colorectal NeoplasmsTumor MicroenvironmentAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesBiomarkers, Tumorcolorectal cancerGlasgow microenvironment scorehaematoxylin and eosin staininghistopathologyimmune infiltrationKlintrup–Mäkinen gradeprognostic biomarkerstromal invasiontumour buddingtumour microenvironmenttumour stroma percentage

Identifiers

PMID38650367
PMCPMC11035902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.